{"entity":{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","aka":[],"tldr":"Candel makes viral immunotherapies injected into tumours to trigger an immune attack. Its lead product, aglatimagene, improved disease-free survival when added to radiotherapy in localised prostate cancer in a phase 3 trial, and a US approval filing is planned for late 2026.","summary":"Candel Therapeutics is a Needham, Massachusetts clinical-stage company developing multimodal viral immunotherapies. Lead candidate aglatimagene besadenovec (CAN-2409), an adenoviral immunotherapy, showed a statistically significant improvement in disease-free survival when added to standard radiotherapy in a pivotal phase 3 trial in localised, intermediate- to high-risk prostate cancer (published in The Lancet Oncology); a BLA submission is planned for the fourth quarter of 2026 with a potential US launch in 2027. The global pivotal phase 3 AURORA trial in stage IV non-squamous non-small cell lung cancer progressing on pembrolizumab has opened enrolment. CAN-3110 (linoserpaturev), an HSV-based oncolytic immunotherapy, is being planned for a randomised phase 2 trial in recurrent glioblastoma. Candel had $201.6 million in cash at 30 June 2026 with runway into the first quarter of 2028. Nasdaq: CADL.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://candeltx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm"},{"label":"Board appointment noting planned BLA (8-K exhibit 99.1, September 2026)","url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm"}],"tags":[],"related":[],"cancers":["prostate","nsclc","glioblastoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct01436968","nct02768363","nct07332000","nct04495153"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Needham, MA","country":"US","companyType":"biotech","website":"https://candeltx.com/","ticker":"CADL","stage":"public","investors":[],"funding":[]},"route":"/companies/candel-therapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"drug":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/"}],"trial":[{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/"},{"id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/"},{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/"},{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","route":"/trials/nct01436968/"},{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","route":"/trials/nct02768363/"}]}}